MYRIAD GENETICS INC
Myriad Genetics, Inc. (NASDAQ: MYRM) is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being through genetic insights and personalized testing solutions. The company develops and commercializes molecular tests that assess disease risk, guide treatment decisions,… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MYRIAD GENETICS INC does
In the company’s own words
Myriad Genetics, Inc. (NASDAQ: MYRM) is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being through genetic insights and personalized testing solutions. The company develops and commercializes molecular tests that assess disease risk, guide treatment decisions, and support earlier detection across multiple medical specialties. Myriad operates approximately 2,700 full-time equivalent employees and maintains laboratory facilities in West Salt Lake City, Utah and South San Francisco, California, with commercial operations spanning the United States, Japan, Europe, and Asia-Pacific regions.
The company organizes its business around three primary segments: Oncology, Women's Health, and Mental Health. In Oncology, Myriad offers comprehensive testing throughout the cancer care continuum, including hereditary cancer risk assessment through MyRisk, companion diagnostics such as BRACAnalysis CDx and MyChoice CDx for therapy selection, prognostic tests like Prolaris for prostate cancer and EndoPredict for breast cancer, and molecular residual disease monitoring through Precise MRD. The Women's Health segment includes prenatal screening tests such as Prequel and the emerging FirstGene multiple prenatal screen, carrier screening through Foresight, and early gender detection via SneakPeek. Mental Health offerings center on GeneSight, a pharmacogenomic test helping clinicians optimize psychotropic medication selection.
Myriad's competitive advantages include its reputation for high-quality testing and customer service, established commercial reach in community medicine, proprietary diagnostic biomarkers and gene expression signatures, and an extensive intellectual property portfolio with patents extending through 2040. The company leverages technology-enabled operations, advanced automation, and digital platforms including electronic medical records integrations to enhance provider access and patient experience. Recent strategic collaborations with PATHOMIQ and SOPHiA GENETICS expand Myriad's oncology capabilities through artificial intelligence-driven diagnostics and liquid biopsy solutions. The company maintains strong brand recognition through trademarks including BRACAnalysis, MyRisk, MyChoice, Prolaris, Prequel, Foresight, GeneSight, and SneakPeek, positioning itself as a trusted partner for precision medicine solutions across major disease areas.
Company details
- Sector
- Materials
- Industry
- Chemicals
- Headquarters
- SALT LAKE CITY, UT
- Fiscal year end
- December
- CIK
- 899923
- SIC
- 2835
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MYRIAD GENETICS INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MYRIAD GENETICS INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MYRIAD GENETICS INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MYRIAD GENETICS INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MYRIAD GENETICS INC's last four quarterly filings that the numbers alone won't show?”